文献速递泌尿生殖MRUS

MRI后经直肠显微超声引导移行区PI-RADS>2病灶活检

Post-MRI transrectal micro-ultrasonography of transition zone PI-RADS > 2 lesions for biopsy guidance.
PubMed 文献 · Eur Radiol · 2022-04-22

前瞻性纳入84例至少一个移行区PI-RADS>2病灶的男性,行MRI引导的显微超声及活检;显微超声对移行区临床显著前列腺癌的病灶水平敏感度83%、特异度28.9%,患者水平敏感度86.4%、特异度27.5%,阅片者间一致性几乎完美(kappa=0.88)。

要点

  • 显微超声可显示77%(71/92)的移行区PI-RADS>2病灶,敏感度83%。
  • 显微超声可见肿瘤较不可见者体积更大、平均ADC值更低(p=0.02)。
  • 不可见肿瘤呈不均匀非特异性回声或被淀粉样小体声影遮挡。

核心结论

  • MRI靶向经直肠显微超声可有效检测移行区临床显著前列腺癌,经直肠超声-MRI图像融合有助于克服移行区组织异质性带来的局限。

研究设计与样本

  • 前瞻性研究,纳入84例连续男性(66±6.3岁),平均PSA 10.2±7.4 ng/mL,至少一个移行区PI-RADS>2病灶,均行MRI引导的显微超声及活检。

关键影像表现/征象

  • 显微超声可见肿瘤较不可见肿瘤体积更大(15.8±5.1 vs. 12.5±3.6 mm)且平均ADC值更低(0.82±1.1×10^3 vs. 0.9±1.4×10^-3 mm²/s)(p=0.02)。
  • 不可见肿瘤表现为不均匀非特异性回声纹理或被淀粉样小体所致声影遮挡。

诊断标准与关键数值

  • 显微超声显示移行区PI-RADS>2病灶的敏感度83%(39/47;95% CI:69.2-92.4%)、特异度28.9%(13/45;95% CI:16.4-44.3%)(病灶水平)。
  • 患者水平敏感度86.4%(38/45;95% CI:72.6-94.8%)、特异度27.5%(11/40;95% CI:14.6-43.9%)。
  • 移行区临床显著前列腺癌检出率51.1%(47/92)。
  • 阅片者间检测显微超声阳性病灶一致性几乎完美(kappa=0.88;95% CI:0.79-0.95)。

临床应用与阅片要点

  • 77%(71/92)的PI-RADS>2移行区病灶可在显微超声下可见并无需图像融合直接活检,22.8%(21/92)不可见病灶需图像融合。
  • 经直肠超声-MRI图像融合仅用于克服良性前列腺增生组织异质性所致的局限。

局限性

  • 主要局限性为研究的单中心性质。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To prospectively determine the value of post-MRI micro-ultrasonography (microUS) in the diagnosis of transition zone (TZ) significant prostate cancer (sPCa).

PATIENTS AND METHODS: Eighty-four consecutive men (66 ± 6.3 years) with a mean PSA level of 10.2 ± 7.4 ng/mL and at least one TZ-PI-RADS > 2 lesion were included. All patients had MRI-directed microUS and biopsy. Sensitivity and specificity of post-MRI microUS to visualize PI-RADS > 2 TZ lesions, the cancer detection rate of TZ-sPCa, and tumor characteristics according to their visibility on microUS were evaluated. Interreader agreement for detecting microUS+ lesions was evaluated using Cohen's kappa test.

RESULTS: Of the 92 PI-RADS > 2 lesions, 71 (71/92; 77%) were visible on microUS and biopsy was performed without image fusion, which was required for the 21 invisible lesions (21/92; 22.8%). TZ-sPCa detection rate was 51.1% (47/92). Sensitivity and specificity of MRI-directed microUS were 83% (39/47; 95% CI: 69.2-92.4%) and 28.9% (13/45; 95% CI: 16.4-44.3%), on a per-lesion basis and 86.4% (38/45; 95% CI: 72.6-94.8%) and 27.5% (11/40; 95% CI: 14.6-43.9%) on a per-patient basis. Visible tumors on microUS exhibited a larger volume and a lower mean ADC value than non-visible tumors (15.8 ± 5.1 vs. 12.5 ± 3.6 mm and 0.82 ± 1.1 × 103 vs. 0.9 ± 1.4 × 10-3 mm2/s) (p = 0.02). Non-visible tumors showed a heterogeneous non-specific echotexture or were masked by the shadowing caused by corpora amylacea. Interreader agreement was almost perfect (kappa = 0.88; 95% CI: 0.79-0.95). The main limitation is the single-center feature of the study.

CONCLUSION: MRI-targeted transrectal microUS is effective to detect TZ-sPCa. TRUS-MRI image fusion helps overcome limitations due to TZ tissue heterogeneity.

KEY POINTS: microUS can visualize the majority of MRI-detected PI-RADS > 2 TZ lesions (sensitivity = 83%). Interreader agreement of MRI-directed microUS in the detection of TZ lesions appears excellent (kappa = 0.88). In 77% of PI-RADS > 2 TZ lesions, biopsy was performed under microUS visual control. MRI fusion system was only used to overcome limitations due to tissue heterogeneity of benign prostatic hyperplasia.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Cornud, Lefevre, Camparo, et al. Post-MRI transrectal micro-ultrasonography of transition zone PI-RADS > 2 lesions for biopsy guidance. Eur Radiol. 2022. PMID: 35451606. doi:10.1007/s00330-022-08788-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。